F-star Therapeutics, Inc. (FSTX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
F-star Therapeutics, Inc. (FSTX) with AI Score 65/100 (Buy). F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing tetravalent bispecific antibodies for cancer therapy. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026F-star Therapeutics, Inc. (FSTX) Healthcare & Pipeline Overview
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in tetravalent bispecific antibodies for immuno-oncology. Their lead candidate, FS118, targets PD-1/PD-L1 resistance in head and neck cancer, positioning them in the competitive cancer therapeutics market with innovative antibody technology.
Investment Thesis
F-star Therapeutics presents a notable research candidate due to its innovative tetravalent bispecific antibody platform and promising clinical pipeline. The Phase 2 trial of FS118 in head and neck cancer patients offers a near-term catalyst for potential value creation. Positive data from this trial could lead to accelerated development and potential partnerships. The company's early-stage assets, including FS222, FS120, and SB 11285, provide further upside potential. However, the inherent risks associated with clinical-stage biotechnology companies, including regulatory hurdles and clinical trial failures, should be considered. The company's beta of -0.35 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- FS118 is in Phase 2 clinical trials targeting PD-1/PD-L1 acquired resistance head and neck cancer patients.
- FS222, a bispecific antibody targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, is in Phase 1 clinical trials.
- FS120 and SB 11285 are being evaluated in Phase 1 clinical trials for patients with advanced cancers.
- F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
- The company employs 84 individuals, indicating a focused and agile operational structure.
Competitors & Peers
Strengths
- Innovative tetravalent bispecific antibody platform.
- Clinical-stage pipeline with multiple assets.
- Experienced management team.
- Focus on immuno-oncology, a rapidly growing market.
Weaknesses
- Reliance on clinical trial success.
- High cash burn rate.
- Competition from larger pharmaceutical companies.
- Limited commercial infrastructure.
Catalysts
- Upcoming: Data readout from the Phase 2 trial of FS118 in head and neck cancer patients (expected in late 2026).
- Upcoming: Initiation of Phase 2 trials for FS222 in additional cancer indications (expected in early 2027).
- Ongoing: Progress in clinical trials for FS120 and SB 11285.
- Ongoing: Potential for new partnerships and collaborations.
Risks
- Potential: Clinical trial failures for FS118 or other pipeline assets.
- Potential: Regulatory delays or rejection of marketing applications.
- Ongoing: Competition from other immuno-oncology therapies.
- Ongoing: Dependence on external funding to support research and development activities.
- Potential: Patent challenges or loss of intellectual property protection.
Growth Opportunities
- Expansion of FS118 into Additional Indications: F-star has the opportunity to expand the use of FS118 beyond head and neck cancer into other solid tumors that exhibit PD-1/PD-L1 resistance. This could significantly increase the addressable market for FS118, potentially reaching a multi-billion dollar market size within the next 3-5 years, contingent on successful clinical trials and regulatory approvals.
- Advancement of FS222 and Other Pipeline Assets: Progressing FS222 and other early-stage assets through clinical development represents a key growth opportunity. Positive data from Phase 1 trials could attract partnerships or licensing agreements, providing non-dilutive funding and validation of F-star's technology platform. The timeline for significant revenue generation from these assets is likely 5-7 years, assuming successful clinical development and regulatory approval.
- Strategic Partnerships and Collaborations: F-star can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its assets. Collaborations can provide access to resources, expertise, and global market reach. The timing of such partnerships is uncertain but could occur within the next 1-3 years, depending on clinical trial progress and business development efforts.
- Expansion of Bispecific Antibody Platform: F-star's tetravalent bispecific antibody platform can be leveraged to develop new therapies targeting different cancer pathways and indications. This platform approach allows for the creation of a pipeline of novel immunotherapies, providing long-term growth potential. The development of new assets from the platform is an ongoing process, with new candidates potentially entering clinical trials within the next 2-4 years.
- Potential for Acquisition: Given its innovative technology and promising pipeline, F-star could be an attractive acquisition target for larger pharmaceutical companies seeking to expand their immuno-oncology portfolios. An acquisition could provide significant value to F-star's shareholders. The timing of a potential acquisition is difficult to predict but could occur within the next 2-3 years, depending on market conditions and the company's clinical progress.
Opportunities
- Expansion into new cancer indications.
- Strategic partnerships and collaborations.
- Out-licensing of pipeline assets.
- Acquisition by a larger pharmaceutical company.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other immuno-oncology therapies.
- Patent challenges.
Competitive Advantages
- Proprietary tetravalent bispecific antibody platform.
- Clinical-stage pipeline of novel immuno-oncology therapies.
- Intellectual property protection for its antibody technology.
About FSTX
F-star Therapeutics, Inc., founded in 2002 and headquartered in Cambridge, UK, is a biopharmaceutical company focused on developing novel cancer therapies. The company specializes in tetravalent bispecific antibodies, a unique approach to immuno-oncology. These antibodies are designed to simultaneously bind to two different targets, enhancing the immune system's ability to fight cancer cells. F-star's lead product candidate, FS118, is currently undergoing a Phase 2 clinical trial to evaluate its effectiveness in treating head and neck cancer patients who have developed resistance to PD-1/PD-L1 inhibitors. In addition to FS118, F-star has several other programs in its pipeline. FS222, a bispecific antibody targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, is in Phase 1 clinical trials. The company is also evaluating FS120 and SB 11285 in Phase 1 clinical trials for patients with advanced cancers. F-star's research and development efforts are centered on creating innovative immunotherapies that can address unmet needs in cancer treatment. The company's tetravalent bispecific antibody platform represents a differentiated approach in the competitive biotechnology landscape, with the potential to improve patient outcomes and expand treatment options.
What They Do
- Develop tetravalent bispecific antibodies for cancer therapy.
- Focus on immuno-oncology treatments.
- Evaluate FS118 in a Phase 2 trial for head and neck cancer.
- Develop FS222, a bispecific antibody, in Phase 1 clinical trial.
- Evaluate FS120 and SB 11285 for patients with advanced cancers in Phase 1 clinical trials.
- Design antibodies to simultaneously bind to two different targets, enhancing the immune system's ability to fight cancer cells.
Business Model
- Develop and out-license novel tetravalent bispecific antibodies.
- Generate revenue through partnerships and collaborations with pharmaceutical companies.
- Advance drug candidates through clinical trials to increase their value and attract potential acquirers.
Industry Context
F-star Therapeutics operates within the competitive biotechnology industry, which is characterized by rapid innovation and high-risk, high-reward opportunities. The immuno-oncology market, in particular, is experiencing significant growth, driven by the increasing prevalence of cancer and the demand for more effective treatments. F-star's focus on bispecific antibodies positions it within a growing segment of the market, as these therapies offer the potential to overcome limitations of traditional monoclonal antibodies. Competitors include companies developing similar immuno-oncology therapies, such as aTyr Pharma (ATYR), DBV Technologies (DBTX), and others.
Key Customers
- Pharmaceutical companies seeking to expand their immuno-oncology portfolios.
- Cancer patients who may benefit from novel immunotherapies.
- Healthcare providers who prescribe cancer treatments.
Financials
Chart & Info
F-star Therapeutics, Inc. (FSTX) stock price: Price data unavailable
Latest News
-
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
benzinga · Jun 23, 2022
-
Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021
· Apr 8, 2021
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FSTX.
Price Targets
Wall Street price target analysis for FSTX.
MoonshotScore
What does this score mean?
The MoonshotScore rates FSTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Eliot Richard Forster
CEO
Eliot Richard Forster serves as the CEO of F-star Therapeutics, bringing extensive experience in the biopharmaceutical industry. His career spans various leadership roles in both large pharmaceutical companies and smaller biotech firms. Prior to joining F-star, he held significant positions at companies such as Creabilis and BioFocus DPI. Forster's background includes a strong foundation in drug development and commercialization, with a focus on oncology and immunology. He holds advanced degrees in relevant scientific disciplines, providing him with a deep understanding of the technical aspects of the business.
Track Record: Under Eliot Richard Forster's leadership, F-star Therapeutics has advanced its pipeline of tetravalent bispecific antibodies into clinical development. Key milestones include the initiation of Phase 2 trials for FS118 and the advancement of FS222 into Phase 1 trials. Forster has also overseen strategic partnerships and collaborations to support the company's research and development efforts. His focus on innovation and strategic execution has positioned F-star as a player in the immuno-oncology space.
F-star Therapeutics, Inc. Stock: Key Questions Answered
What does F-star Therapeutics, Inc. do?
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of tetravalent bispecific antibodies for cancer therapy. Their innovative approach focuses on immuno-oncology, where they engineer antibodies to simultaneously bind to two different targets on cancer cells and immune cells. This unique mechanism enhances the immune system's ability to recognize and destroy cancer cells. The company's lead product candidate, FS118, is currently in Phase 2 clinical trials, targeting head and neck cancer patients who have developed resistance to PD-1/PD-L1 inhibitors. F-star's pipeline also includes other bispecific antibodies in earlier stages of development, aimed at addressing various cancer types.
What do analysts say about FSTX stock?
Analyst coverage of FSTX is currently limited due to its clinical-stage nature and inherent risks associated with biotechnology companies. However, the company's innovative tetravalent bispecific antibody platform and promising clinical pipeline have garnered some attention. Key valuation metrics are difficult to assess at this stage, as the company does not yet have any products on the market. Growth considerations are primarily focused on the successful completion of clinical trials and potential partnerships with larger pharmaceutical companies. Analyst sentiment will likely shift significantly based on clinical trial results and regulatory milestones. It is important to note that investment in clinical-stage biotech companies carries substantial risk.
What are the main risks for FSTX?
The primary risks for F-star Therapeutics, Inc. are inherent to its status as a clinical-stage biopharmaceutical company. These include the potential for clinical trial failures, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining marketing approvals also pose a significant risk. Competition from larger pharmaceutical companies with greater resources and established market presence is another factor. Additionally, F-star relies on external funding to support its research and development activities, making it vulnerable to changes in market conditions and investor sentiment. Protecting its intellectual property through patents is also crucial, as challenges to its patents could undermine its competitive advantage.
What are the key factors to evaluate for FSTX?
F-star Therapeutics, Inc. (FSTX) currently holds an AI score of 65/100, indicating moderate score. Key strength: Innovative tetravalent bispecific antibody platform.. Primary risk to monitor: Potential: Clinical trial failures for FS118 or other pipeline assets.. This is not financial advice.
How frequently does FSTX data refresh on this page?
FSTX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FSTX's recent stock price performance?
Recent price movement in F-star Therapeutics, Inc. (FSTX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative tetravalent bispecific antibody platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FSTX overvalued or undervalued right now?
Determining whether F-star Therapeutics, Inc. (FSTX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FSTX?
Before investing in F-star Therapeutics, Inc. (FSTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for FSTX.
- Financial data is limited; investment decisions should be made with caution.